Roy M Fleischmann (Roy Fleischmann)

ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 80

Top Venues

RMD open

Annals of the rheumatic diseases

Arthritis & rheumatology (Hoboken, N.J.)

Rheumatology and therapy

University of Texas Southwestern Medical Center at Dallas

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University of Texas Southwestern Medical Center at Dallas Jan 01 1990

United States

Clinical Professor of Medicine :: Rheumatology

Rheumatology Associates Apr 01 1978

United States

MD :: Rheumatology

Publications

Eric F Morand, Joseph F Merola, Yoshiya Tanaka, Dafna D Gladman, Roy M Fleischmann
TYK2: an emerging therapeutic target in rheumatic disease. Nature reviews. Rheumatology 20 (4) (2024)
Roy M Fleischmann, Jerzy Swierkot, Sara K Penn, Patrick Durez, Louis Bessette, Xianwei Bu, Nasser Khan, Yihan Li, Charles G Peterfy, Yoshiya Tanaka, Eduardo Mysler
Long-term safety and efficacy of upadacitinib versus adalimumab in patients with rheumatoid arthritis: 5-year data from the phase 3, randomised SELECT-COMPARE study. RMD open 10 (2) (2024)
Eric F Morand, Joseph F Merola, Yoshiya Tanaka, Dafna D Gladman, Roy M Fleischmann
TYK2: an emerging therapeutic target in rheumatic disease. Nature reviews. Rheumatology 20 (4) (2024)
Roy M Fleischmann, Jerzy Swierkot, Sara K Penn, Patrick Durez, Louis Bessette, Xianwei Bu, Nasser Khan, Yihan Li, Charles G Peterfy, Yoshiya Tanaka, Eduardo Mysler
Long-term safety and efficacy of upadacitinib versus adalimumab in patients with rheumatoid arthritis: 5-year data from the phase 3, randomised SELECT-COMPARE study. RMD open 10 (2) (2024)
Ronald F Van Vollenhoven, Stephen Hall, Alvin F Wells, Sebastian Meerwein, Yanna Song, Oishi Tanjinatus, Roy M Fleischmann
Long-term sustainability of response to upadacitinib among patients with active rheumatoid arthritis refractory to biological treatments: results up to 5 years from SELECT-BEYOND. RMD open 10 (3) (2024)
Zoltán Szekanecz, Maya H Buch, Christina Charles-Schoeman, James B Galloway, George Athanasios Karpouzas, Lars Erik Kristensen, Steven R Ytterberg, Attila Hamar, Roy M Fleischmann
Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician. Nature reviews. Rheumatology (2024)
Christina Charles-Schoeman, Roy M Fleischmann, Eduardo Mysler, Maria Greenwald, Steven R Ytterberg, Gary G Koch, Deepak L Bhatt, Cunshan Wang, Ted R Mikuls, All-Shine Chen, Carol A Connell, John C Woolcott, Sujatha Menon, Yan Chen, Kristen Lee, Zoltán Szekanecz
Risk of Venous Thromboembolism with Tofacitinib Versus Tumor Necrosis Factor Inhibitors in Cardiovascular Risk-enriched Rheumatoid Arthritis Patients. Arthritis & rheumatology (Hoboken, N.J.) (2024)
Roy M Fleischmann, Jerzy Swierkot, Sara K Penn, Patrick Durez, Louis Bessette, Xianwei Bu, Nasser Khan, Yihan Li, Charles G Peterfy, Yoshiya Tanaka, Eduardo Mysler
Long-term safety and efficacy of upadacitinib versus adalimumab in patients with rheumatoid arthritis: 5-year data from the phase 3, randomised SELECT-COMPARE study. RMD open 10 (2) (2024)
Zoltán Szekanecz, Maya H Buch, Christina Charles-Schoeman, James B Galloway, George Athanasios Karpouzas, Lars Erik Kristensen, Steven R Ytterberg, Attila Hamar, Roy M Fleischmann
Publisher Correction: Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician. Nature reviews. Rheumatology (2024)
Roy M Fleischmann, Ricardo Blanco, Filip E Van den Bosch, Louis Bessette, Yanna Song, Sara K Penn, Erin McDearmon-Blondell, Nasser Khan, Kelly Chan, Eduardo Mysler
Long-term Efficacy and Safety Following Switch Between Upadacitinib and Adalimumab in Patients with Rheumatoid Arthritis: 5-Year Data from SELECT-COMPARE. Rheumatology and therapy (2024)
Roy M Fleischmann, Sebastian Meerwein, Christina Charles-Schoeman, Bernard G Combe, Stephen Hall, Nasser Khan, Kyle M Carter, Heidi S Camp, Andrea Rubbert-Roth
Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-BEYOND study. RMD open 10 (3) (2024)
Eric F Morand, Joseph F Merola, Yoshiya Tanaka, Dafna D Gladman, Roy M Fleischmann
TYK2: an emerging therapeutic target in rheumatic disease. Nature reviews. Rheumatology (2024)
Ronald F Van Vollenhoven, Stephen Hall, Alvin F Wells, Sebastian Meerwein, Yanna Song, Oishi Tanjinatus, Roy M Fleischmann
Long-term sustainability of response to upadacitinib among patients with active rheumatoid arthritis refractory to biological treatments: results up to 5 years from SELECT-BEYOND. RMD open 10 (3) (2024)
Eugen Feist, Roy M Fleischmann, Saeed Fatenejad, Daria Bukhanova, Sergey Grishin, Sofia Kuzkina, Michael Luggen, Evgeniy Nasonov, Mikhail Samsonov, Josef S Smolen
Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment. Annals of the rheumatic diseases (2024)
Christina Charles-Schoeman, Roy M Fleischmann, Eduardo Mysler, Maria Greenwald, Steven R Ytterberg, Gary G Koch, Deepak L Bhatt, Cunshan Wang, Ted R Mikuls, All-Shine Chen, Carol A Connell, John C Woolcott, Sujatha Menon, Yan Chen, Kristen Lee, Zoltán Szekanecz
Risk of Venous Thromboembolism With Tofacitinib Versus Tumor Necrosis Factor Inhibitors in Cardiovascular Risk-Enriched Rheumatoid Arthritis Patients. Arthritis & rheumatology (Hoboken, N.J.) 76 (8) (2024)
Zoltán Szekanecz, Maya H Buch, Christina Charles-Schoeman, James B Galloway, George Athanasios Karpouzas, Lars Erik Kristensen, Steven R Ytterberg, Attila Hamar, Roy M Fleischmann
Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician. Nature reviews. Rheumatology 20 (2) (2024)
Roy M Fleischmann, Jerzy Swierkot, Sara K Penn, Patrick Durez, Louis Bessette, Xianwei Bu, Nasser Khan, Yihan Li, Charles G Peterfy, Yoshiya Tanaka, Eduardo Mysler
Long-term safety and efficacy of upadacitinib versus adalimumab in patients with rheumatoid arthritis: 5-year data from the phase 3, randomised SELECT-COMPARE study. RMD open 10 (2) (2024)
Christina Charles-Schoeman, Roy M Fleischmann, Eduardo Mysler, Maria Greenwald, Steven R Ytterberg, Gary G Koch, Deepak L Bhatt, Cunshan Wang, Ted R Mikuls, All-Shine Chen, Carol A Connell, John C Woolcott, Sujatha Menon, Yan Chen, Kristen Lee, Zoltán Szekanecz
Risk of Venous Thromboembolism With Tofacitinib Versus Tumor Necrosis Factor Inhibitors in Cardiovascular Risk-Enriched Rheumatoid Arthritis Patients. Arthritis & rheumatology (Hoboken, N.J.) (2024)
Roy M Fleischmann, Sebastian Meerwein, Christina Charles-Schoeman, Bernard G Combe, Stephen Hall, Nasser Khan, Kyle M Carter, Heidi S Camp, Andrea Rubbert-Roth
Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-BEYOND study. RMD open 10 (3) (2024)
Roy M Fleischmann, Ricardo Blanco, Filip E Van den Bosch, Louis Bessette, Yanna Song, Sara K Penn, Erin McDearmon-Blondell, Nasser Khan, Kelly Chan, Eduardo Mysler
Long-term Efficacy and Safety Following Switch Between Upadacitinib and Adalimumab in Patients with Rheumatoid Arthritis: 5-Year Data from SELECT-COMPARE. Rheumatology and therapy 11 (3) (2024)
Ronald F Van Vollenhoven, Stephen Hall, Alvin F Wells, Sebastian Meerwein, Yanna Song, Oishi Tanjinatus, Roy M Fleischmann
Long-term sustainability of response to upadacitinib among patients with active rheumatoid arthritis refractory to biological treatments: results up to 5 years from SELECT-BEYOND. RMD open 10 (3) (2024)
Roy M Fleischmann, Ricardo Blanco, Filip E Van den Bosch, Louis Bessette, Yanna Song, Sara K Penn, Erin McDearmon-Blondell, Nasser Khan, Kelly Chan, Eduardo Mysler
Long-term Efficacy and Safety Following Switch Between Upadacitinib and Adalimumab in Patients with Rheumatoid Arthritis: 5-Year Data from SELECT-COMPARE. Rheumatology and therapy 11 (3) (2024)
Roy M Fleischmann, Sebastian Meerwein, Christina Charles-Schoeman, Bernard G Combe, Stephen Hall, Nasser Khan, Kyle M Carter, Heidi S Camp, Andrea Rubbert-Roth
Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-BEYOND study. RMD open 10 (3) (2024)
Roy M Fleischmann, Sebastian Meerwein, Christina Charles-Schoeman, Bernard G Combe, Stephen Hall, Nasser Khan, Kyle M Carter, Heidi S Camp, Andrea Rubbert-Roth
Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-BEYOND study. RMD open 10 (3) (2024)
Eric F Morand, Joseph F Merola, Yoshiya Tanaka, Dafna D Gladman, Roy M Fleischmann
TYK2: an emerging therapeutic target in rheumatic disease. Nature reviews. Rheumatology (2024)
Roy M Fleischmann, Ricardo Blanco, Filip E Van den Bosch, Louis Bessette, Yanna Song, Sara K Penn, Erin McDearmon-Blondell, Nasser Khan, Kelly Chan, Eduardo Mysler
Long-term Efficacy and Safety Following Switch Between Upadacitinib and Adalimumab in Patients with Rheumatoid Arthritis: 5-Year Data from SELECT-COMPARE. Rheumatology and therapy 11 (3) (2024)
Zoltán Szekanecz, Maya H Buch, Christina Charles-Schoeman, James B Galloway, George Athanasios Karpouzas, Lars Erik Kristensen, Steven R Ytterberg, Attila Hamar, Roy M Fleischmann
Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician. Nature reviews. Rheumatology 20 (2) (2024)
Roy M Fleischmann, Ricardo Blanco, Filip E Van den Bosch, Louis Bessette, Yanna Song, Sara K Penn, Erin McDearmon-Blondell, Nasser Khan, Kelly Chan, Eduardo Mysler
Long-term Efficacy and Safety Following Switch Between Upadacitinib and Adalimumab in Patients with Rheumatoid Arthritis: 5-Year Data from SELECT-COMPARE. Rheumatology and therapy 11 (3) (2024)
Zoltán Szekanecz, Maya H Buch, Christina Charles-Schoeman, James B Galloway, George Athanasios Karpouzas, Lars Erik Kristensen, Steven R Ytterberg, Attila Hamar, Roy M Fleischmann
Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician. Nature reviews. Rheumatology 20 (2) (2024)
Eric F Morand, Joseph F Merola, Yoshiya Tanaka, Dafna D Gladman, Roy M Fleischmann
TYK2: an emerging therapeutic target in rheumatic disease. Nature reviews. Rheumatology 20 (4) (2024)
Roy M Fleischmann, Sebastian Meerwein, Christina Charles-Schoeman, Bernard G Combe, Stephen Hall, Nasser Khan, Kyle M Carter, Heidi S Camp, Andrea Rubbert-Roth
Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-BEYOND study. RMD open 10 (3) (2024)
Roy M Fleischmann
Is there a role for vagal nerve stimulation in the treatment of rheumatoid arthritis? Arthritis & rheumatology (Hoboken, N.J.) (2023)
Janet E Pope, Roy M Fleischmann
Jack pot! What can we learn about registries with respect to treatment cycling in rheumatoid arthritis? Annals of the rheumatic diseases 82 (2) (2023)
Janet E Pope, Roy M Fleischmann
Jack pot! What can we learn about registries with respect to treatment cycling in rheumatoid arthritis? Annals of the rheumatic diseases (2023)
Chun Wu, Yanhua Hu, Peter Schafer, Sean E Connolly, Robert Wong, Signe Holm Nielsen, Anne-Christine Bay-Jensen, Paul Emery, Yoshiya Tanaka, Vivian P Bykerk, Clifton O Bingham, Thomas Wj Huizinga, Roy M Fleischmann, Jinqi Liu
Baseline serum levels of cross-linked carboxy-terminal telopeptide of type I collagen predict abatacept treatment response in methotrexate-naive, anticitrullinated protein antibody-positive patients with early rheumatoid arthritis. RMD open 8 (2) (2023)
Chun Wu, Yanhua Hu, Peter Schafer, Sean E Connolly, Robert Wong, Signe Holm Nielsen, Anne-Christine Bay-Jensen, Paul Emery, Yoshiya Tanaka, Vivian P Bykerk, Clifton O Bingham, Thomas Wj Huizinga, Roy M Fleischmann, Jinqi Liu
Baseline serum levels of cross-linked carboxy-terminal telopeptide of type I collagen predict abatacept treatment response in methotrexate-naive, anticitrullinated protein antibody-positive patients with early rheumatoid arthritis. RMD open 8 (2) (2023)
Peter C Taylor, Michael E Weinblatt, Iain B McInnes, Tatsuya Atsumi, Vibeke Strand, Tsutomu Takeuchi, Marguerite Bracher, David Brooks, John Davies, Christopher Goode, Anubha Gupta, Sumanta Mukherjee, Ciara O'Shea, Didier Saurigny, Lorrie A Schifano, Celia Shelton, Julia E Smith, Millie Wang, Reena Wang, Sarah Watts, Roy M Fleischmann
Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3). Annals of the rheumatic diseases (2023)
Janet E Pope, Roy M Fleischmann
Jack pot! What can we learn about registries with respect to treatment cycling in rheumatoid arthritis? Annals of the rheumatic diseases 82 (2) (2023)
Chun Wu, Yanhua Hu, Peter Schafer, Sean E Connolly, Robert Wong, Signe Holm Nielsen, Anne-Christine Bay-Jensen, Paul Emery, Yoshiya Tanaka, Vivian P Bykerk, Clifton O Bingham, Thomas Wj Huizinga, Roy M Fleischmann, Jinqi Liu
Baseline serum levels of cross-linked carboxy-terminal telopeptide of type I collagen predict abatacept treatment response in methotrexate-naive, anticitrullinated protein antibody-positive patients with early rheumatoid arthritis. RMD open 8 (2) (2023)
Roy M Fleischmann, Désirée Mfm van der Heijde, Vibeke Strand, Tatsuya Atsumi, Iain B McInnes, Tsutomu Takeuchi, Peter C Taylor, Marguerite Bracher, David Brooks, John Davies, Christopher Goode, Anubha Gupta, Sumanta Mukherjee, Ciara O'Shea, Didier Saurigny, Lorrie A Schifano, Celia Shelton, Julia E Smith, Millie Wang, Reena Wang, Sarah Watts, Michael E Weinblatt
Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2). Annals of the rheumatic diseases (2023)
Chun Wu, Yanhua Hu, Peter Schafer, Sean E Connolly, Robert Wong, Signe Holm Nielsen, Anne-Christine Bay-Jensen, Paul Emery, Yoshiya Tanaka, Vivian P Bykerk, Clifton O Bingham, Thomas Wj Huizinga, Roy M Fleischmann, Jinqi Liu
Baseline serum levels of cross-linked carboxy-terminal telopeptide of type I collagen predict abatacept treatment response in methotrexate-naive, anticitrullinated protein antibody-positive patients with early rheumatoid arthritis. RMD open 8 (2) (2023)
Eugen Feist, Saeed Fatenejad, Sergey Grishin, Elena Korneva, Michael E Luggen, Evgeniy Nasonov, Mikhail Samsonov, Josef S Smolen, Roy M Fleischmann
Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III study. Annals of the rheumatic diseases 81 (12) (2022)
Roy M Fleischmann, Eduardo Mysler, Louis Bessette, Charles G Peterfy, Patrick Durez, Yoshiya Tanaka, Jerzy Swierkot, Nasser Khan, Xianwei Bu, Yihan Li, In-Ho Song
Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study. RMD open 8 (1) (2022)
Daniel Aletaha, Andreas Kerschbaumer, Kastriot Kastrati, Christian Dejaco, Maxime Dougados, Iain B McInnes, Naveed Sattar, Tanja Alexandra Stamm, Tsutomu Takeuchi, Michael Trauner, Désirée Mfm van der Heijde, Marieke Voshaar, Kevin L Winthrop, Angelo Ravelli, Neil Betteridge, Gerd-Rüdiger R Burmester, Johannes W J Bijlsma, Vivian Bykerk, Roberto Caporali, Ernest H S Choy, Catalin Codreanu, Bernard Combe, Mary K Crow, Maarten P T de Wit, Paul Emery, Roy M Fleischmann, Cem Gabay, Merete Lund Hetland, Kimmie L Hyrich, AnnaMaria Iagnocco, John Dudley Isaacs, Joel M Kremer, Xavier Mariette, Peter A Merkel, Eduardo F Mysler, Peter Nash, Michael T Nurmohamed, Karel Pavelka, Gyula Poor, Andrea Rubbert-Roth, Hendrik Schulze-Koops, Anja Strangfeld, Yoshiya Tanaka, Josef S Smolen
Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update. Annals of the rheumatic diseases (2022)
Roy M Fleischmann, Amy E Bock, Wuyan Zhang, Charles M Godfrey, Ivana Vranic, Carol Cronenberger, Eva Dokoupilová
Usability Study of PF-06410293, an Adalimumab Biosimilar, by Prefilled Pen: Open-Label, Single-Arm, Sub-Study of a Phase 3 Trial in Patients with Rheumatoid Arthritis. Rheumatology and therapy 9 (3) (2022)
Peter C Taylor, Rieke E Alten, Jose María Álvaro Gracia, Yuko Kaneko, Chad Walls, Amanda Quebe, Bochao Jia, Natalia Bello, Jorge Ross Terres, Roy M Fleischmann
Achieving pain control in early rheumatoid arthritis with baricitinib monotherapy or in combination with methotrexate versus methotrexate monotherapy. RMD open 8 (1) (2022)
Roy M Fleischmann, Kyle Hayes, Sung-Woo Ahn, George J Wan, Mary Panaccio, Daniel Karlsson, Daniel E Furst
Post Hoc Analysis of Predictors of Clinical Response to Repository Corticotropin Injection in Persistently Active Rheumatoid Arthritis. Rheumatology and therapy 9 (2) (2022)
Roy M Fleischmann
Biologic disease-modifying anti-rheumatic drugs and kinase inhibitors: differences in efficacy and safety in rheumatoid arthritis. Clinical rheumatology 40 (11) (2021)
Roy M Fleischmann, Jingyu Liu, Julie Zhu, Oscar G Segurado, Daniel E Furst
Discrepancy Between Multi-Biomarker Disease Activity and Clinical Disease Activity Scores in Patients With Persistently Active Rheumatoid Arthritis. Arthritis care & research (2021)
Mark C Genovese, Patrick Durez, Roy M Fleischmann, Yoshiya Tanaka, Daniel E Furst, Hisashi Yamanaka, Elena Korneva, Igor Vasyutin, Tsutomu Takeuchi
Long-term safety and efficacy of olokizumab in patients with rheumatoid arthritis and inadequate response to tumor necrosis factor inhibitor therapy in phase II studies. European journal of rheumatology (2021)
Roy M Fleischmann, Daniel F Alvarez, Amy E Bock, Carol Cronenberger, Ivana Vranic, Wuyan Zhang, Rieke E Alten
Randomised study of PF-06410293, an adalimumab (ADL) biosimilar, compared with reference ADL for the treatment of active rheumatoid arthritis: results from weeks 26-52, including a treatment switch from reference ADL to PF-06410293. RMD open 7 (2) (2021)
Kurt de Vlam, Alexis Ogdie, Andrew G Bushmakin, Joseph C Cappelleri, Roy M Fleischmann, Peter C Taylor, Valderilio Azevedo, Lara Fallon, John Woolcott, Phillip J Mease
Median time to pain improvement and the impact of baseline pain severity on pain response in patients with psoriatic arthritis treated with tofacitinib. RMD open 7 (2) (2021)
Roy M Fleischmann
The Results of Well-conducted Negative Clinical Trials Should Be Reported in a Peer-reviewed Journal. The Journal of rheumatology 48 (7) (2021)
Roy M Fleischmann, Daniel F Alvarez, Amy E Bock, Carol Cronenberger, Ivana Vranic, Wuyan Zhang, Rieke Alten
Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52-92 data from a randomized, double-blind, phase 3 trial. Arthritis research & therapy 23 (1) (2021)
Christine Liu, Jacqueline Kieltyka, Roy M Fleischmann, Massimo Gadina, John J O'Shea
A Decade of JAK Inhibitors: What Have We Learned and What May Be the Future? Arthritis & rheumatology (Hoboken, N.J.) 73 (12) (2021)
Janet E Pope, Peter Nash, Roy M Fleischmann
Current Treatment Strategies in Rheumatoid Arthritis After Methotrexate Are Not Enough to Maintain Sustained Remission: There Is No Holy Grail! Arthritis & rheumatology (Hoboken, N.J.) 73 (7) (2021)
Roy M Fleischmann, Kyle Hayes, Sung-Woo Ahn, George J Wan, Mary P Panaccio, Daniel Karlsson, Daniel E Furst
Post Hoc Analysis of the Correlation Between Patient-Reported Outcomes and Clinical Response to Repository Corticotropin Injection for Persistently Active Rheumatoid Arthritis. Rheumatology and therapy 9 (2) (2021)
Andreas Kerschbaumer, Josef S Smolen, Peter Nash, Thomas Dörner, Maxime Dougados, Roy M Fleischmann, Klaus Geissler, Iain B McInnes, Tsutomu Takeuchi, Michael Trauner, Kevin Winthrop, Maarten P T de Wit, Wolf-Henning Boehncke, Louise Falzon, Désirée Mfm van der Heijde
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature research. RMD open 6 (3) (2021)
Tsutomu Takeuchi, Roy M Fleischmann, Noriko Iikuni, Harry Shi, Koshika Soma, Jerome Paulissen, Tomohiro Hirose, Josef S Smolen
Differences and similarities in clinical and functional responses among patients receiving tofacitinib monotherapy, tofacitinib plus methotrexate, and adalimumab plus methotrexate: a post hoc analysis of data from ORAL Strategy. Arthritis research & therapy 23 (1) (2021)
Roy M Fleischmann
EULAR PsA management recommendations 2019: can the recommendations be improved? Annals of the rheumatic diseases 79 (6) (2020)
Roy M Fleischmann, Tsutomu Takeuchi, Michael Schiff, Douglas Schlichting, Li Xie, Maher Issa, Ivaylo Stoykov, Jeffrey Lisse, Pindaro Martinez-Osuna, Terence Rooney, Cristiano A F Zerbini
Efficacy and Safety of Long-Term Baricitinib With and Without Methotrexate for the Treatment of Rheumatoid Arthritis: Experience With Baricitinib Monotherapy Continuation or After Switching From Methotrexate Monotherapy or Baricitinib Plus Methotrexate. Arthritis care & research 72 (8) (2020)
Peter Nash, Andreas Kerschbaumer, Thomas Dörner, Maxime Dougados, Roy M Fleischmann, Klaus Geissler, Iain McInnes, Janet E Pope, Désirée Mfm van der Heijde, Michaela Stoffer-Marx, Tsutomu Takeuchi, Michael Trauner, Kevin L Winthrop, Maarten P T de Wit, Daniel Aletaha, Xenofon Baraliakos, Wolf-Henning Boehncke, Paul Emery, John D Isaacs, Joel Kremer, Eun Bong Lee, Walter P Maksymowych, Marieke Voshaar, Lai-Shan Tam, Yoshiya Tanaka, Filip van den Bosch, René Westhovens, Ricardo Xavier, Josef S Smolen
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. Annals of the rheumatic diseases 80 (1) (2020)
Roy M Fleischmann
2019 update of the American College of Rheumatology- recommended rheumatoid arthritis disease activity measures: comment on the article by England et al. Arthritis care & research 72 (5) (2020)
Roy M Fleischmann, Ricardo Blanco-Alonso, Stephen Hall, Glen T D Thomson, Filip E Van den Bosch, Cristiano Zerbini, Louis Bessette, Jeffrey Enejosa, Yihan Li, Yanna Song, Ryan DeMasi, In-Ho Song
Switching between Janus kinase inhibitor upadacitinib and adalimumab following insufficient response: efficacy and safety in patients with rheumatoid arthritis. Annals of the rheumatic diseases (2020)
Leonard H Calabrese, Carlos Abud-Mendoza, Stephen M Lindsey, Sang-Heon Lee, Svitlana Tatulych, Liza Takiya, Noriko Iikuni, Koshika Soma, Zhen Luo, Roy M Fleischmann
Live Zoster Vaccine in Patients With Rheumatoid Arthritis Treated With Tofacitinib With or Without Methotrexate, or Adalimumab With Methotrexate: A Post Hoc Analysis of Data From a Phase IIIb/IV Randomized Study. Arthritis care & research 72 (3) (2020)
Yannick Degboe, Michael Schiff, Michael Weinblatt, Roy M Fleischmann, Harris A Ahmad, Arnaud Constantin
Background Glucocorticoid Therapy Has No Impact on Efficacy and Safety of Abatacept or Adalimumab in Patients with Rheumatoid Arthritis. Journal of clinical medicine 9 (6) (2020)
Kevin L Winthrop, Masayoshi Harigai, Mark C Genovese, Stephen Lindsey, Tsutomu Takeuchi, Roy M Fleischmann, John D Bradley, Nicole L Byers, David L Hyslop, Maher Issa, Atsushi Nishikawa, Terence P Rooney, Sarah Witt, Christina L Dickson, Josef S Smolen, Maxime Dougados
Infections in baricitinib clinical trials for patients with active rheumatoid arthritis. Annals of the rheumatic diseases 79 (10) (2020)
Roy M Fleischmann, Vipul Jairath, Eduardo Mysler, Dave Nicholls, Paul Declerck
Nonmedical Switching From Originators to Biosimilars: Does the Nocebo Effect Explain Treatment Failures and Adverse Events in Rheumatology and Gastroenterology? Rheumatology and therapy 7 (1) (2020)
Roy M Fleischmann
Looking Back on 2019 in Rheumatology and What to Expect from 2020. Rheumatology and therapy 7 (1) (2019)
Roy M Fleischmann
Value of the Multibiomarker Disease Activity Score to Predict Remission in RA: What Does the Evidence Show? The Journal of rheumatology 46 (5) (2019)
Roy M Fleischmann, Aileen L Pangan, In-Ho Song, Eduardo Mysler, Louis Bessette, Charles Peterfy, Patrick Durez, Andrew J Ostor, Yihan Li, Yijie Zhou, Ahmed A Othman, Mark C Genovese
Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial. Arthritis & rheumatology (Hoboken, N.J.) 71 (11) (2019)
Roy M Fleischmann
Dr. Fleischmann replies. The Journal of rheumatology 46 (12) (2019)
Roy M Fleischmann, Henning Bliddal, Francisco Javier Blanco, Thomas J Schnitzer, Charles Peterfy, Su Chen, Li Wang, Sheng Feng, Philip G Conaghan, Francis Berenbaum, Jean-Pierre Pelletier, Johanne Martel-Pelletier, Ole Vaeterlein, Gurjit S Kaeley, Wei Liu, Matthew P Kosloski, Gwen Levy, Lanju Zhang, Jeroen K Medema, Marc C Levesque
A Phase II Trial of Lutikizumab, an Anti-Interleukin-1α/β Dual Variable Domain Immunoglobulin, in Knee Osteoarthritis Patients With Synovitis. Arthritis & rheumatology (Hoboken, N.J.) 71 (7) (2019)
Vibeke Strand, Eduardo Mysler, Robert John Moots, Gene V Wallenstein, Ryan DeMasi, David Gruben, Koshika Soma, Noriko Iikuni, Josef S Smolen, Roy M Fleischmann
Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trial. RMD open 5 (2) (2019)
Désirée van der Heijde, Vibeke Strand, Yoshiya Tanaka, Edward Keystone, Joel Kremer, Cristiano A F Zerbini, Mario H Cardiel, Stanley Cohen, Peter Nash, Yeong-Wook Song, Dana Tegzová, David Gruben, Gene Wallenstein, Carol A Connell, Roy M Fleischmann, null null
Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty-Four-Month, Phase III Study. Arthritis & rheumatology (Hoboken, N.J.) 71 (6) (2019)
Joseph F Merola, Luis R Espinoza, Roy M Fleischmann
Distinguishing rheumatoid arthritis from psoriatic arthritis. RMD open 4 (2) (2018)
Roy M Fleischmann, Rieke Alten, Margarita Pileckyte, Kasia Lobello, Steven Y Hua, Carol Cronenberger, Daniel Alvarez, Amy E Bock, K Lea Sewell
A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis. Arthritis research & therapy 20 (1) (2018)
Roy M Fleischmann
Editorial: The American College of Rheumatology White Paper on Biosimilars: It Isn't All White-There Is Some Gray and Black. Arthritis & rheumatology (Hoboken, N.J.) 70 (3) (2018)
Désirée Mfm van der Heijde, Atul Deodhar, Oliver FitzGerald, Roy M Fleischmann, Dafna Gladman, Alice B Gottlieb, Bengt Hoepken, Lars Bauer, Oscar Irvin-Sellers, Majed Khraishi, Luke Peterson, Anthony Turkiewicz, Jürgen Wollenhaupt, Philip J Mease
4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis. RMD open 4 (1) (2018)
Roy M Fleischmann, Peter Winkle, Jesse Hall, Shakti Valdez, Sha Liu, Xiaohong Yan, Liz Hicks, Caroline Lee, Jeffrey N Miner, Michael Gillen, Martha Hernandez-Illas
Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with febuxostat in adults with gout: a phase IIa, open-label study. RMD open 4 (1) (2018)

Roy M Fleischmann.css-eqlu8i{font-size:small;padding-left:4px;} (Roy Fleischmann)

Publication Activity (10 Years)

Top Topics

Top Venues

Roy M Fleischmann (Roy Fleischmann)